Efficacy and safety of nivolumab plus chemotherapy in patients with advanced gastric cancer with massive ascites

doi:10.4251/wjgo.v18.i1.112944

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-4) series.

Item

Count

PDF

HTML

Figures (1-4)

Tables (1-4)

Sum=13

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=17

Jan 15, 2026 (publication date) through Jan 12, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Jan 15, 2026; 18(1): 112944
Published online Jan 15, 2026. doi: 10.4251/wjgo.v18.i1.112944

Open in New Tab Full Size Figure Download Figure

Figure 1 Study flow. AGC: Advanced gastric cancer.

Open in New Tab Full Size Figure Download Figure

Figure 2 Kaplan-Meier curves of progression-free survival and overall survival in all patients. A: Progression-free survival; B: Overall survival. PFS: Progression-free survival; OS: Overall survival.

Open in New Tab Full Size Figure Download Figure

Figure 3 Kaplan-Meier estimates of progression-free survival and overall survival according to low ascites burden and high ascites burden. A: Progression-free survival; B: Overall survival. LAB: Low ascites burden; HAB: High ascites burden.

Open in New Tab Full Size Figure Download Figure

Figure 4 Kaplan-Meier estimates of progression-free survival and overall survival according to programmed cell death ligand 1 expression in patients with high ascites burden. A: Progression-free survival; B: Overall survival. CPS: Combined positive score; PD-L1: Programmed cell death ligand 1.

Citation: Matsumoto T, Sugimoto S, Omori R, Makiyama C, Nakasya A, Nagai H, Yasui H, Higashi R, Sasamoto A, Satake H. Efficacy and safety of nivolumab plus chemotherapy in patients with advanced gastric cancer with massive ascites. World J Gastrointest Oncol 2026; 18(1): 112944
URL: https://www.wjgnet.com/1948-5204/full/v18/i1/112944.htm
DOI: https://dx.doi.org/10.4251/wjgo.v18.i1.112944